Immune checkpoint blockade (ICB) therapies have achieved clinical benefit, but most
'immune-cold'solid tumors are not responsive. The diversity of immune evasion mechanisms …

The approval of the first immune checkpoint inhibitors provided a paradigm shift for the
treatment of malignancies across a broad range of indications. Whereas initially, single …

Hepatocellular carcinoma (HCC) is a prevalent disease with a progression that is modulated
by the immune system. Systemic therapy is used in the advanced stage and until 2017 …

Immunotherapy, represented by immune checkpoint inhibitors (ICIs), has greatly improved
the clinical efficacy of malignant tumor therapy. ICI-mediated antitumor responses depend …

Intratumoral immune cells are crucial for tumor control and antitumor responses during
immunotherapy. Immune cell trafficking into tumors is mediated by binding of specific …

Melanoma, a skin cancer that develops from pigment cells, has been studied intensively,
particularly in terms of the immune response to tumours, and has been used as a model for …

Immunotherapy has revolutionized cancer treatment and substantially improved patient
outcome with regard to multiple tumour types. However, most patients still do not benefit …

Immune checkpoint inhibitors, including antibodies that block programmed cell death protein-
1 (PD-1) and PD-L1, have transformed the management of many cancers. However, the …

Abstract 'Immune checkpoint blockade'for cancer describes the use of therapeutic antibodies
that disrupt negative immune regulatory checkpoints and unleash pre-existing antitumour …

Purpose: This phase I study assessed the safety, pharmacokinetics (PKs), and efficacy of
MIW815 (ADU-S100), a novel synthetic cyclic dinucleotide that activates the stimulator of IFN …